$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm

$atnm Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039902 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue			$940.0K
YoY Change			51.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.561M	$3.735M	$1.735M
YoY Change	41.08%	115.27%	0.99%
% of Gross Profit
Research & Development	$11.08M	$7.849M	$4.369M
YoY Change	137.69%	79.65%	2.17%
% of Gross Profit
Depreciation & Amortization	$209.0K	$182.0K	$137.0K
YoY Change	16.11%	32.85%	9.6%
% of Gross Profit
Operating Expenses	$15.64M	$11.58M	$6.104M
YoY Change	98.13%	89.78%	1.84%
Operating Profit	-$15.64M	-$11.58M	-$5.164M
YoY Change	99.26%	124.32%
Interest Expense	$461.0K	$547.0K	$35.00K
YoY Change	455.42%	1462.86%	-32.69%
% of Operating Profit
Other Income/Expense, Net	$461.0K	$547.0K	$35.00K
YoY Change	455.42%	1462.86%
Pretax Income	-$15.18M	-$11.04M	-$5.129M
YoY Change	95.46%	115.19%	-3.59%
Income Tax
% Of Pretax Income
Net Earnings	-$15.18M	-$11.04M	-$5.129M
YoY Change	95.46%	115.19%	-3.59%
Net Earnings / Revenue			-545.64%
Basic Earnings Per Share	-$0.58	-$0.43	-$0.23
Diluted Earnings Per Share	-$0.58	-$0.43	-$231.6K
COMMON SHARES
Basic Shares Outstanding	26.41M shares	25.73M shares	22.14M shares
Diluted Shares Outstanding	26.22M shares	25.70M shares	22.14M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$91.28M	$94.52M	$72.02M
YoY Change	-21.54%	31.25%	-0.32%
Cash & Equivalents	$91.28M	$94.52M	$72.02M
Short-Term Investments
Other Short-Term Assets	$4.261M	$4.024M	$2.034M
YoY Change	116.62%	97.84%	36.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$95.54M	$98.55M	$74.05M
YoY Change	-19.24%	33.07%	0.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$624.0K	$630.0K	$509.0K
YoY Change	12.03%	23.77%	-43.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$307.0K	$304.0K
YoY Change	2.68%
Total Long-Term Assets	$3.514M	$3.480M	$509.0K
YoY Change	0.31%	583.69%	-62.3%
TOTAL ASSETS
Total Short-Term Assets	$95.54M	$98.55M	$74.05M
Total Long-Term Assets	$3.514M	$3.480M	$509.0K
Total Assets	$99.05M	$102.0M	$74.56M
YoY Change	-18.68%	36.83%	-0.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.637M	$7.358M	$5.261M
YoY Change	49.77%	39.86%	41.16%
Accrued Expenses	$512.0K	$503.0K	$154.0K
YoY Change	75.34%	226.62%	-55.87%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000K	$3.000K	$41.00K
YoY Change	-89.47%	-92.68%	-53.41%
Total Short-Term Liabilities	$9.151M	$7.864M	$5.723M
YoY Change	45.67%	37.41%	37.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.000K
YoY Change	-100.0%	-100.0%	-95.35%
Other Long-Term Liabilities	$36.82M	$36.95M
YoY Change	-1.37%
Total Long-Term Liabilities	$36.82M	$36.95M	$2.000K
YoY Change	-1.38%	1847600.0%	-98.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.151M	$7.864M	$5.723M
Total Long-Term Liabilities	$36.82M	$36.95M	$2.000K
Total Liabilities	$45.97M	$44.82M	$5.725M
YoY Change	5.4%	682.85%	31.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$315.0M	-$299.8M
YoY Change	17.25%
Common Stock	$27.00K	$26.00K
YoY Change	8.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.08M	$57.21M	$68.84M
YoY Change
Total Liabilities & Shareholders Equity	$99.05M	$102.0M	$74.56M
YoY Change	-18.68%	36.83%	-0.71%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$15.18M	-$11.04M	-$5.129M
YoY Change	95.46%	115.19%	-3.59%
Depreciation, Depletion And Amortization	$209.0K	$182.0K	$137.0K
YoY Change	16.11%	32.85%	9.6%
Cash From Operating Activities	-$13.64M	-$15.08M	-$5.781M
YoY Change	-148.87%	160.8%	2.46%
INVESTING ACTIVITIES
Capital Expenditures	$47.00K	$76.00K	-$7.000K
YoY Change	-117.41%	-1185.71%	75.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$47.00K	-$76.00K	-$7.000K
YoY Change	-82.59%	985.71%	75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.05M	$770.0K	-22.00K
YoY Change	-39.7%	-3600.0%	-100.15%
NET CHANGE
Cash From Operating Activities	-13.64M	-$15.08M	-5.781M
Cash From Investing Activities	-47.00K	-$76.00K	-7.000K
Cash From Financing Activities	10.05M	$770.0K	-22.00K
Net Change In Cash	-3.642M	-$14.38M	-5.810M
YoY Change	-108.22%	147.56%	-166.83%
FREE CASH FLOW
Cash From Operating Activities	-$13.64M	-$15.08M	-$5.781M
Capital Expenditures	$47.00K	$76.00K	-$7.000K
Free Cash Flow	-$13.69M	-$15.15M	-$5.774M
YoY Change	-148.57%	162.44%	2.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36374
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	74-2963609
CY2023Q1	dei	City Area Code CityAreaCode	(646)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	677-3870
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	275 Madison Avenue, 7th Fl
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10016
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, par value $0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	dei	Trading Symbol TradingSymbol	ATNM
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26409826	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94522000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108910000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	399000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	396000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3625000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1636000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	98546000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	110942000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	536000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	487000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	630000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	604000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	304000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	302000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2544000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2341000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3000	usd
CY2023Q1	us-gaap	Assets Assets	102026000	usd
CY2022Q4	us-gaap	Assets Assets	114192000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	7358000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	10130000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	494000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7864000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10628000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	35000000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	35000000	usd
CY2023Q1	atnm	Longterm Operating Lease Obligations Noncurrent LongtermOperatingLeaseObligationsNoncurrent	1954000	usd
CY2022Q4	atnm	Longterm Operating Lease Obligations Noncurrent LongtermOperatingLeaseObligationsNoncurrent	2083000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	44818000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	47711000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25729370	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25729370	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25674823	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25674823	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	26000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	26000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	356984000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	355220000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-299802000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288765000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	57208000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	66481000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102026000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	114192000	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	940000	usd
CY2022Q1	us-gaap	Revenues Revenues	940000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7849000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4369000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3735000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1735000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	11584000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	6104000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11584000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5164000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	547000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	35000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	547000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11037000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5129000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25696623	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22143974	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66481000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	993000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	770000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11037000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57208000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73545000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	421000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5129000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68837000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11037000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5129000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	993000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	421000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	137000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1989000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	114000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2770000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-275000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-731000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-336000	usd
CY2023Q1	atnm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-120000	usd
CY2022Q1	atnm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-90000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15077000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5781000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-76000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	22000	usd
CY2023Q1	atnm	Sales Of Shares Of Common Stock Net Of Costs SalesOfSharesOfCommonStockNetOfCosts	770000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	770000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-22000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14383000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5810000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109608000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78221000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95225000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72411000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>- The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	94522000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	108910000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	399000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	396000	usd
CY2023Q1	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	304000	usd
CY2022Q4	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	302000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	95225000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	109608000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5092	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3385	shares
CY2012Q2	atnm	Milestone Payment MilestonePayment	1000000	usd
CY2012Q2	us-gaap	Derivative Net Assets Percentage DerivativeNetAssetsPercentage	0.02	pure
CY2023Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	5 years 2 months
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2027-07-30
CY2023Q1	us-gaap	Lease Cost LeaseCost	600000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	162000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	93000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	20000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	21000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	150000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	94000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	usd
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	22000	usd
CY2023Q1	atnm	Schedule Or Description Of Weighted Average Term ScheduleOrDescriptionOfWeightedAverageTerm	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td>Weighted average remaining lease term:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 years</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.8 year</span></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q1	atnm	Schedule Of Weighted Average Discount Rate ScheduleOfWeightedAverageDiscountRate	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td>Weighted average discount rates:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p>
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.048	pure
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q1	atnm	Revenue Recognized RevenueRecognized	800000	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000	usd
CY2022Q2	atnm	Upfront Payment UpfrontPayment	35000000	usd
CY2023Q1	atnm	Longterm License Revenue Deferred LongtermLicenseRevenueDeferred	35000000	usd
CY2022Q4	atnm	Longterm License Revenue Deferred LongtermLicenseRevenueDeferred	35000000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3396000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M6D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	15204000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	11000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.89
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	82000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.76
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3324000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.07
CY2023Q1	atnm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y6M
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	11114000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	975000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.66
CY2023Q1	atnm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted	P7Y2M15D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2304000	usd
CY2023Q1	atnm	Rs Us Outstanding Beginning Balance RSUsOutstandingBeginningBalance	325	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.96
CY2023Q1	atnm	Rs Us Outstanding Ending Balance RSUsOutstandingEndingBalance	325	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.96
CY2023Q1	atnm	Shares Of Common Stock Value SharesOfCommonStockValue	600000	shares
CY2023Q1	atnm	Net Proceeds NetProceeds	5600000	usd
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Actinium Pharmaceuticals, Inc.
CY2023Q1	us-gaap	Sublease Income SubleaseIncome		usd
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22143974	shares
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities		usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2022Q1	atnm	Sales Of Shares Of Common Stock Net Of Costs SalesOfSharesOfCommonStockNetOfCosts		usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001388320

Files In Submission

Name	View Source	Status
atnm-20230331_def.xml	Edgar Link	unprocessable
atnm-20230331_pre.xml	Edgar Link	unprocessable
atnm-20230331_lab.xml	Edgar Link	unprocessable
0001213900-23-039902-index-headers.html	Edgar Link	pending
0001213900-23-039902-index.html	Edgar Link	pending
0001213900-23-039902.txt	Edgar Link	pending
0001213900-23-039902-xbrl.zip	Edgar Link	pending
atnm-20230331.xsd	Edgar Link	pending
f10q0323ex31-1_actiniumphar.htm	Edgar Link	pending
f10q0323ex31-2_actiniumphar.htm	Edgar Link	pending
f10q0323ex32-1_actiniumphar.htm	Edgar Link	pending
f10q0323ex32-2_actiniumphar.htm	Edgar Link	pending
f10q0323_actiniumphar.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
img_002.jpg	Edgar Link	pending
img_003.jpg	Edgar Link	pending
img_004.jpg	Edgar Link	pending
atnm-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_actiniumphar_htm.xml	Edgar Link	completed
img_005.jpg	Edgar Link	pending
img_006.jpg	Edgar Link	pending
img_007.jpg	Edgar Link	pending
img_008.jpg	Edgar Link	pending
img_009.jpg	Edgar Link	pending
img_010.jpg	Edgar Link	pending
img_011.jpg	Edgar Link	pending
img_012.jpg	Edgar Link	pending
img_013.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm

2023 Q2 Form 10-Q Financial Statement

#000121390023039902 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNM Actinium Pharmaceuticals, Inc. Stock $atnm

2023 Q2 Form 10-Q Financial Statement

#000121390023039902 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm